Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial

RCT (n=812) found high remission rates for all treatments; 42.7% for active conventional treatment, 46.5% for certolizumab, 52.0% for abatacept, 42.1% for tocilizumab. Only abatacept was statistically superior to active conventional treatment (difference = +9.4%, p<0.05).

Source:

British Medical Journal